Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Read More ... Contact Us. Jim DeNike. Senior ...

Mar 5, 2024 · Director, Corporate Communications & Investor Relations Marinus Pharmaceuticals, Inc. investors@marinuspharma.com. Quick Links. SEC Filings ...

Marinus Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 05/09/2024. The upcoming earnings date is derived from an algorithm based on a ...

Mar 5, 2024 · (Nasdaq: MRNS), a pharmaceutical company ... financial performance, financial position ... Director, Corporate Communications & Investor Relations.

Senior VP of Investor Relations, Human Resources & Corporate Affairs, N/A, N/A, N/A. Ms. Martha E. Manning Esq., J. D., Senior VP, General Counsel & Secretary ...

Feb 21, 2024 · (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...

Find the latest Marinus Pharmaceuticals, Inc. Common Stock (MRNS) annual income statements, balance sheets, financial statements, ratios, and cash flow data ...

NASDAQ: MRNS ... The listing above does not imply endorsement or concurrent with their information, conclusions, or recommendations. Investor Relations – Nasdaq: ...

Finance · Historical Data · Options · Statistics

Company Contact Sasha Damouni Ellis Senior Vice President, Corporate Affairs & Investor Relations Marinus Pharmaceuticals, Inc. sdamouni@marinuspharma.com.